# The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

> **NCT02505945** · PHASE4 · COMPLETED · sponsor: **Torax Medical Incorporated** · enrollment: 152 (actual)

## Conditions studied

- GERD Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Omeprazole
- **DEVICE:** LINX Reflux Management System

## Key facts

- **NCT ID:** NCT02505945
- **Lead sponsor:** Torax Medical Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-10
- **Final completion:** 2018-08
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2019-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02505945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02505945, "The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02505945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*